Context Therapeutics Inc. Common Stock earnings per share and revenue
On Nov 05, 2025, CNTX reported earnings of -0.10 USD per share (EPS) for Q3 25, missing the estimate of -0.09 USD, resulting in a -4.06% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.10 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Context Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Context Therapeutics Inc. Common Stock reported EPS of -$0.10, missing estimates by -4.06%, and revenue of $0.00, 0% as expectations.
How did the market react to Context Therapeutics Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -5.31%, changed from $1.13 before the earnings release to $1.07 the day after.
When is Context Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 12, 2026.
What are the forecasts for Context Therapeutics Inc. Common Stock's next earnings report?
Based on 11
analysts, Context Therapeutics Inc. Common Stock is expected to report EPS of -$0.10 and revenue of -- for Q4 2025.